

Listing of All Claims Including Current Amendments

1-48 (Previously cancelled)

49. (Cancelled)

50-52 (Previously cancelled)

53-56 (Cancelled)

57-58 (Previously cancelled)

59-64 (Cancelled)

65 (Previously cancelled)

66 (Cancelled)

67 (Previously cancelled)

68-69 (Cancelled)

70 (Previously cancelled)

71-73 (Cancelled)

74 (Previously cancelled)

75-77 (Cancelled)

78 (Previously cancelled)

79-82 (Cancelled)

83. (Currently Amended) A method for treating a subject for Type I allergies that are IgE mediated comprising coadministering-administering to the subject a therapeutically effective amount of an agent selected from the group consisting of Etx, Ctx, EtxB agent, and CtxB; and an antigen/allergen; wherein said agent is not coupled to the anti-gen/allergen that binds to GM1, wherein if the agent is coadministered with an anti-gen/allergen the agent and the antigen/allergen are not coupled.

84. (New) A method according to claim 83 wherein the Type I allergies that are IgE mediated are selected from the group consisting of asthma, allergic cough, allergic

rhinitis, conjunctivitis, atopic eczema, dermatitis, urticaria, hives, insect bite allergy, dietary allergy and drug allergies.

85. (New) A method according to claim 84 wherein the allergy is asthma.

86. (New) A method according to claim 84 wherein the allergy is allergic rhinitis.

87. (New) A method according to claim 83 wherein the agent is formulated in a pharmaceutically acceptable carrier.

88. (New) A method according to claim 83 wherein the agent is administered mucosally, intravenously, intramuscularly or subcutaneously.

89. (New) A method for treating a subject for IgE mediated Type I allergies, excluding non-IgE mediated insect bite allergies, dietary allergies and drug allergies, comprising administering to the subject a therapeutically effective amount of an EtxB agent that binds to GM1, wherein if the agent is coadministered with an antigen/allergen the agent and the antigen/allergen are not coupled.

90. (New) A method according to claim 89 wherein the IgE mediated Type I allergies are one or more of asthma, allergic rhinitis, conjunctivitis, atopic eczema, dermatitis, urticaria, and hives,

91. (New) A method according to claim 89 wherein the allergy is asthma.

92. (New) A method according to claim 89 wherein the allergy is allergic rhinitis.

93. (New) A method according to claim 89 wherein the agent is formulated in a pharmaceutically acceptable carrier.

94. (New) A method according to claim 89 wherein the agent is administered mucosally, intravenously, intramuscularly or subcutaneously.

95. (New) A method for treating a subject for IgE mediated Type I allergies, excluding non-IgE mediated insect bite allergies, dietary allergies and drug allergies, comprising administering to the subject a therapeutically effective amount of an EtxB agent that binds to GM1, together with an allergen which is not coupled to the EtxB agent.

96. (New) A method according to claim 95 wherein the IgE mediated Type I allergies are one or more of asthma, allergic rhinitis, conjunctivitis, atopic eczema, dermatitis, urticaria, and hives,

97. (New) A method according to claim 95 wherein the allergy is asthma.

98. (New) A method according to claim 95 wherein the allergy is allergic rhinitis.

99. (New) A method according to claim 95 wherein the agent is formulated in a pharmaceutically acceptable carrier.

100. (New) A method according to claim 95 wherein the agent is administered mucosally, intravenously, intramuscularly or subcutaneously.